Treatment with daratumumab can rapidly deplete CD38+ Tregs, MDSCs, and Bregs and is associated with clonal expansion of CD4+ and CD8+ T cells in myeloma patients (Figure 3). This evidence concerns the gene CD38 and plasma cell myeloma.